How do COPD patients respond to exacerbations?

BMC Pulm Med. 2011 Aug 19:11:43. doi: 10.1186/1471-2466-11-43.

Abstract

Background: Although timely treatment of COPD exacerbations seems clinically important, nearly half of these exacerbations remain unreported and subsequently untreated. Recent studies have investigated incidence and impact of failure to seek medical treatment during exacerbations. Yet, little is known about type and timing of other self-management actions in periods of symptom deterioration. The current prospective study aims at determining the relative incidence, timing and determinants of three types of patient responses.

Methods: In a multicentre observational study, 121 patients (age 67 ± 11 years, FEV1pred. 48 ± 19) were followed for 6 weeks by daily diary symptom recording. Three types of action were assessed daily: planning periods of rest, breathing techniques and/or sputum clearing (type-A), increased bronchodilator use (type-B) and contacting a healthcare provider (type-C).

Results: Type-A action was taken in 70.7%, type-B in 62.7% and type C in 17.3% of exacerbations (n = 75). Smokers were less likely to take type-A and B actions. Type-C actions were associated with more severe airflow limitation and increased number of hospital admissions in the last year.

Conclusions: Our study shows that most patients are willing to take timely self-management actions during exacerbations. Future research is needed to determine whether the low incidence of contacting a healthcare provider is due to a lack of self-management or healthcare accessibility.

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Aged
  • Breathing Exercises*
  • Bronchodilator Agents / therapeutic use*
  • Female
  • Health Services Accessibility
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Patient Participation
  • Physician-Patient Relations*
  • Prospective Studies
  • Pulmonary Disease, Chronic Obstructive / therapy*
  • Rest*
  • Self Care
  • Sputum*
  • Time Factors
  • Treatment Outcome

Substances

  • Bronchodilator Agents